The Rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 6, 2012, Pages 1545-1555

  Takeba, Yuko ^a   Matsumoto, Naoki ^a   Watanabe, Minoru ^a   Takenoshita Nakaya, Sachiko ^a   Ohta, Yuki ^a   Kumai, Toshio ^a   Takagi, Masayuki ^a   Koizumi, Satoshi ^a   Asakura, Takeshi ^a   Otsubo, Takehito ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Fasudil; Hepatocellular carcinoma; P53; Rho kinase

Indexed keywords

CASPASE 3; CASPASE 9; FASUDIL; PROTEIN BAX; PROTEIN P53; RHO KINASE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER HEMANGIOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LIVER; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863810890     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1862-6     Document Type: Article

References (42)

1. Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, Watanabe G, Tsurumaru M (1993) Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 71:19-25
2. Sugihara S, Kojiro M, Nakashima T (1985) Ultrastructural study of hepatocellular carcinoma with replacing growth pattern. Acta Pathol Jpn 35:549-559
3. Okuda K (2000) Hepatocellular carcinoma. J Hepatol 32:225-237
4. Bergsland EK (2001) Molecular mechanisms underlying the development of hepatocellular carcinoma. Semin Oncol 28:521-531
5. Utsunomiya T, Shimada M (2011) Molecular characteristics of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatol Res 41:711-721
6. Orimo T, Ojima H, Hiraoka N et al (2008) Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-endbinding protein 1 in hepatocellular carcinoma. Hepatology 48:1851-1863
7. Wang W, Peng JX, Yang JQ, Yang LY (2009) Identification of gene expression profiling in hepatocellular carcinoma using cDNA microarrays. Dig Dis Sci 54:2729-2735
8. Frttz G, Just I, Kanita B (1999) Rho GTPase are over-expressed in human tumors. Int J Cancer 81:682-687
9. Gris F, Bidaud A, Moreau V (2009) Rho GTPase in hepatocellular carcinoma. Biochem Biophys Acta 1795:137-151
10. Amano M, Fukata Y, Kaibuchi K (2000) Regulation and functions of Rho associated kinase. Exp Cell Res 261:44-51
11. Sahai E, Marshall CJ (2002) RHO-GTPases and cancer. Nat Rev Cancer 2:133-142
12. Takamura M, Sakamoto M, Genda T, Ichida T, Asakura H, Hirohashi S (2001) Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 33:577-581
13. Fukui K, Tamura S, Wada A et al (2006) Expression and prognostic role of Rho A GTPases in hepatocellular carcinoma. J Cancer Res Clin Oncol 132:627-633
14. Wettschureck N, Offermanns S (2002) Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 80:629-638
15. Tamura M, Nakao H, Yoshizaki H et al (2005) Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta 1754:245-252
16. Ying H, Biroc SL, Li WW et al (2006) The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 5:2158-2164
17. Xue F, Takahara T, Yata Y et al (2008) Blockade of Rho/Rhoassociated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinasedependent manner. Hepatol Res 38:810-817
18. Ogawa T, Tashiro H, Miyata Y et al (2007) Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. Am J Transp 7:347-355
19. Takeba Y, Sekine S, Kumai T et al (2007) Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. Biol Pharm Bull 30:1400-1406
20. Li Q, Liu D, Huang X, Guo L (2011) Fasudil mesylate protects PC12 cells from oxidative stress injury via the Bax-mediated pathway. Cell Mol Neurobiol 31:243-250
21. Grise F, Bidaud A, Moreau V (2009) Rho GTPases in hepatocellular carcinoma. Biochim Biophys Acta 1795:137-151
22. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, Oshima H (2003) Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9:2632-2641
23. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K (1997) Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 275:1308-1311
24. Shi J, Wei L (2007) Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp 55:61-75
25. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5:221-225
26. Genda T, Sakamoto M, Ichida T, Asakura H, Kojiro M, Narumiya S, Hirohashi S (1999) Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology 30:1027-1036
27. Park JW, Park CH, Kim IJ, Bae EH, Ma SK, Lee JU, Kim SW (2011) Rho kinase inhibition by fasudil attenuates cyclosporineinduced kidney injury. J Pharmacol Exp Ther 338:271-279
28. Rattan R, Giri S, Singh AK, Singh I (2006) Rho/ROCK pathway as a target of tumor therapy. J Neurosci Res 83:243-255
29. Iwamoto H, Nakamuta M, Tada S, Sugimoto R, Enjoji M, Nawata H (2000) A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth. J Hepatol 32:762-770
30. Nakashima M, Adachi S, Yasuda I, Yamauchi T, Kozawa O, Moriwaki H (2010) Rho-kinase regulates negatively the epidermal growth factor-stimulated colon cancer cell proliferation. Int J Oncol 36:585-592
31. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42:3858-3863
32. Lin Y, Ong LK, Chan SH (1995) Differential in situ hybridization of mutational specific expression of the p53 gene in human hepatoma cell lines. Pathology 27:191-196
33. Hippenstiel S, Chmeck B, N'Guessan PD, Seybold J, Krüll M, Preissner K, Eichel-Streiber CV, Suttorp N (2002) Rho protein inactivation induced apoptosis of cultured human endothelial cells. Am J Physiol Lung Cell Mol Physiol 283:L830-L838
34. Althoefer H, Eversole-Cire P, Simon MI (1997) Constitutively active Galphaq and Galpha13 trigger apoptosis through different pathways. J Biol Chem 272:24380-24386
35. Cho HJ, Baek KE, Park SM et al (2011) RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Lett 311:48-56
36. Levine AJ, Momand J, Finlay CA (1991) The p53 tumor suppressor gene. Nature 351:453-456
37. Lakin ND, Jackson SP (1999) Regulation of p53 in response to DNA damage. Oncogene 18:7644-7655
38. Lowe SW, Ruley HE, Jacks T, Housman DE (1993) p53- dependent modulates the cytotoxicity of anticancer agents. Cell 74:957-967
39. Takeba Y, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, Yanagida Y, Kobayashi S (2007) Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis. J Pharmacol Sci 104:232-242
40. Hsiao BY, Chen CC, Hsieh PC et al (2011) Rad is a p53 direct transcriptional target that inhibits cell migration and is frequently silenced in lung carcinoma cells. J Mol Med 89:481-492
41. Guo F, Zheng Y (2004) Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion. Oncogene 23:5577-5585
42. Gadea G, de Toledo M, Anguille C, Roux P (2007) Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J Cell Biol 178:23-30